Does weight management research for adults with severe obesity represent them? Analysis of systematic review data

Clare Robertson, Magaly Aceves-Martins, Moira Cruickshank, Mari Imamura, Alison Avenell

ABSTRACT

Objective Our objective was to determine the extent to which current evidence from long-term randomised controlled trials (RCTs) of weight management is generalisable and applicable to underserved adult groups with obesity (body mass index (BMI) ≥ 35 kg/m²).

Methods Descriptive analysis of 131 RCTs, published after 1990–May 2017 with ≥1 year of follow-up, included in a systematic review of long-term weight management interventions for adults with BMI ≥ 35 kg/m² (the REBALANCE Project). Studies were identified from MEDLINE, EMBASE, PsychINFO, SCI, CENTRAL and from hand searching. Reporting of trial inclusion and exclusion criteria, trial recruitment strategies, baseline characteristics and outcomes were analysed using a predefined list of characteristics informed by the PROGRESS (Place of residence, Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, Education, Socioeconomic status, Social capital)–Plus framework and the UK Equality Act 2010.

Results Few (6.1%) trials reported adapting recruitment to appeal to underserved groups. 10.0% reported culturally adapting their trial materials. Only 6.1% of trials gave any justification for their exclusion criteria, yet over half excluded participation for age or mental health reasons. Just over half (58%) of the trials reported participants’ race or ethnicity, and one-fifth reported socioeconomic status. Where outcomes were reported for underserved groups, the most common analysis was by sex (47.3%), followed by race or ethnicity (16.8%). 3.1% of trials reported outcomes according to socioeconomic status.

Discussion Although we were limited by poor trial reporting, our results indicate inadequate representation of people most at risk of obesity. Guidance for considering underserved groups may improve the appropriateness of research and inform greater engagement with health and social care services.

STRENGTHS AND LIMITATIONS OF THIS STUDY

A unique analysis exploring whether randomised trials evaluating interventions for weight management for people with severe obesity consider the needs of underserved groups.

Data set includes up-to-date, best available randomised controlled trial evidence (considered to be the highest level of evidence to inform guidelines and clinical practice) identified using robust and exhaustive literature search strategies.

Data set includes wide-ranging weight management interventions delivered in different settings, from an international perspective.

Our analysis was limited by poor reporting of whether subgroup reporting by underserved groups was planned and whether trials were adequately powered to detect subgroup differences.

Non-randomised study designs, interventions with shorter follow-up and unpublished studies may have been more inclusive in their designs and reporting.

BACKGROUND

In high-income countries, and increasingly in low/middle-income countries, lower incomes, less education, lower socioeconomic status (SES) and disability are associated with greater risk of obesity for adults. While the underlying causes of obesity are varied, there is an increasing association between obesity and deprivation that is driving poorer health outcomes and increasing health inequalities. For example, most of these risk factors are stronger for women than men, although men with obesity may be less likely than women to undertake weight management programmes. Being an adult with obesity is associated with a lower health-related quality of life than a healthy adult of the same SES. More severe obesity, such as body mass index (BMI) ≥ 35 kg/m² or more, with its associated greater risks for comorbidities, reduced quality of life and premature mortality, is particularly related to lower SES and intellectual and physical disabilities. Poorer outcomes from COVID-19 are also strongly
related to obesity, particularly severe obesity.⁵ For countries such as the USA, UK, Australia and New Zealand, some racial or ethnic groups may also be at much greater risk of obesity, especially severe obesity.¹¹⁻¹⁴

Preventing obesity and providing effective interventions, particularly for people with more severe obesity, are, therefore, a major public health challenge and vital in terms of addressing health inequalities. While organisations such as the US Food and Drug Administration,¹⁵⁻¹⁸ the National Institutes of Health (NIH)¹⁹ and the National Institute for Health Research (NIHR)²⁰⁻²¹ have produced guidelines on the inclusion of individuals of all ages, sexes/genders, races and ethnicities, and other physical, sensory/perceptual, cognitive and emotional characteristics, there is a lack of accessible policy-ready evidence on what works in terms of interventions to reduce inequalities in obesity. It is also recognised that some groups (for example, socially disadvantaged, less educated, and minority race or ethnic groups) may be less likely to be recruited into randomised controlled trials (RCTs) for lifestyle interventions.²²⁻²⁴ Similarly, religion²⁵ and sexual orientation²⁶⁻²⁷ have been linked to weight and body image. It is, therefore, important to understand the extent to which the current evidence base is applicable to those who are most at risk of experiencing poorer obesity-related health outcomes and have more severe obesity.

This study aimed to determine the extent to which the findings from intervention studies of weight management, as exemplified by long-term RCTs, are generalisable and applicable to those most at risk, particularly underserved groups with severe obesity. To examine these questions, we set out:

1. To describe inclusion and exclusion criteria for RCTs of adult weight management interventions, and in those trials:
2. To describe efforts to tailor recruitment strategies to improve recruitment of people from underserved groups.
3. To describe efforts to culturally adapt interventions to increase the accessibility or appeal to shared characteristics of an underserved group.
4. To describe reported baseline characteristics and outcomes for these groups.

METHODS

Our data set comprised 131 RCTs included in a systematic review of weight management interventions for adults with BMI ≥35 kg/m², as part of the REBALANCE Project (REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis; NIHR HTA 15/09/04).¹⁰ BMI ≥35 kg/m² was chosen as this is a cut-off often used for accessing bariatric surgery or secondary care weight management clinical services in the UK. Eligible interventions included diet (including, but not limited to, very low-calorie diets and meal replacements), lifestyle (including combination of diet, physical activity and types of counselling), bariatric surgery or orlistat. RCTs were restricted to publications after 1990 up to May 2017 to reflect more recent clinical practice. Literature searching was conducted in June 2016 and updated in April/May 2017. Details of the literature search method and search strategy are available in the online supplemental files. Trials had to report long-term data on weight change (≥1 year of follow-up) and include trial populations with a baseline mean or median BMI ≥35 kg/m². The decision to focus on long-term RCTs for this study was informed by the preference for high-quality, long-term evidence of lasting effectiveness in guideline documents²⁸⁻³⁰ and are, therefore, most likely to influence treatment policy decisions. Reports published as abstracts or conference proceedings only were excluded. Three reviewers screened titles, abstracts and full-text reports with a 10% quality assessment check. We attempted to contact the first, second and last authors of the main publications to identify all additional materials (ie, protocols, trial materials and diet books) to inform our data extraction for the main REBALANCE report. Full details of the completed REBALANCE Project, including the protocol, have been published.¹⁰

In the absence of definitions of underserved groups, we identified underserved groups by using protected characteristics informed by the PROGRESS (Place of residence, Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, Education, Socioeconomic status, Social capital)-Plus framework³¹ and the UK Equality Act 2010.³² Four reviewers (MA-M, MC, MI and CR) conducted double data coding of each RCT for their reporting of whether trials reported details of their inclusion and exclusion criteria, trial recruitment strategies, baseline characteristics and outcome reporting for the following characteristic groups, with disagreements resolved by consensus:

- Older age
- Physical health
- Mental health (including, but not limited to, depression, psychosis, schizophrenia, substance abuse and eating disorders)
- Comorbidities (eg, types 1 and 2 diabetes mellitus)
- Gender/sex (including RCTs recruiting only men or women)
- Sexual orientation
- Gender reassignment
- Marriage or civil partnership status
- Pregnancy
- Religion or belief
- Place of residence/housing (including residents of supported accommodation and homeowner status)
- Race or ethnicity
- Language
- Occupational status
- Education/literacy
- SES, including individual SES and participants recruited from rural or disadvantaged geographical locations
- Social capital (including social support networks and/or social isolation)
PROGRESS-Plus (personal characteristics associated with discrimination (eg, age, disability), features of relationships (eg, smoking parents, excluded from school), time-dependent relationships (eg, leaving the hospital, respite care, other instances where a person may be temporarily at a disadvantage))

For inclusion and exclusion criteria, trials were coded by predefined categories indicating whether any of the characteristic groups were clearly reported in the inclusion/exclusion criteria, or, where details were not reported, whether the setting of the trial encouraged/discouraged inclusion of individuals from a particular characteristic group (eg, recruitment was set in a health centre predominantly serving people from a characteristic group), or by whether it was unclear that the trial included/excluded people from any of the characteristic groups. For baseline and outcome reporting, we coded whether the protected characteristic was reported and, if reported, whether it was reported for individual treatment groups or the trial population as a whole. Where subgroup analyses were reported, we coded these according to whether it was clear/unclear from the study report that analyses were preplanned. For a trial to be coded as having adapted their recruitment strategy for an underserved group, additional efforts to employ strategies that would appeal to that particular group (eg, held recruitment days in particular settings or developed recruitment materials in multiple languages) had to be demonstrated. Trials that solely recruited from one characteristic group using conventional recruitment methods (eg, newspaper or radio advertisements) were not coded as having an adapted recruitment strategy. Similarly, trials had to demonstrate that their interventions were designed with an underserved group in mind to be coded as having delivered a culturally adapted intervention. The focus of this study was to provide a description of trial methods and trial reporting to answer each of our research questions in relation to underserved groups; therefore, no formal statistical analysis was conducted.

Patient and public involvement
Although we did not consult patient representatives for this particular analysis, three patient representatives were members of the REBALANCE Project Advisory Group, who contributed to developing the research questions, data interpretation and reporting of the research findings.

RESULTS
From the total of 131 included trials, 19 were identified from database searching and 112 were identified from autoalert searching. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart and list of included studies are presented in the online supplemental files. Of the 131 trials, 41 (31.3%) provided us with additional materials for their publications for the main REBALANCE report, although most of the information for the current analysis was obtained from the primary publications. The majority (81 of 131, 61.8%) of included studies were set in North America (80 in the USA and 1 in the USA and Canada), 41 out of 131 (31.3%) were in European countries (including 8 in the UK), 8 (6.1%) were in the Southern Hemisphere (6 in Australia, 1 in New Zealand and 1 in Australia and New Zealand) and 1 in Brazil. None of the trials were set in low-income countries. Just under half (62 of 131, 47.3%) of the studies were published between 2011 and 2017. Five (3.8%) trials were linked to publications reporting qualitative data. 34-38 Few trials had follow-up duration longer than 12 months, with the exception of the US Look AHEAD trial39 (median duration of 9.6 years), and four trials with follow-up times of 5 years.40-45 The Look AHEAD trial was the largest trial, including over 5000 participants. Interventions were wide ranging, including very low calorie (19 of 131, 14.5%), orlistat (12 or 131, 9.2%), bariatric surgery (11 of 131, 8.4%) and other lifestyle weight management programmes incorporating diet and physical activity advice (89 of 131, 67.9%). Details of the characteristics of the included studies can be found in the online supplemental files of the REBALANCE report.10

Trial recruitment
More than half of the trials (71 of 131, 54%) recruited participants either solely or partially through a health service provider, for example, either solely from outpatient clinics and general practices,44 45 or by physician referral and targeted mailing.46 Recruitment methods were unclear or not reported in 14 trials (10.7%).47-59 Recruitment methods for the other trials were mainly advertisements in local newspapers or other media. Based on their reporting, only three (2.3%) trials were judged to have adapted their recruitment strategies to appeal to underserved groups.36 60 61 These preplanned strategies included holding pre-recruitment presentations in US schools,60 recruitment events at football stadiums of Scottish Premier League football clubs,36 and having bilingual staff take informed consent and provide written consent forms in both English and Spanish languages.61 It was unclear in a further five (3.8%) trials whether recruitment strategies had been adapted beyond conventional methods.

Regarding adaptions to interventions, seven trials (5.3%, six from the USA and one from New Zealand)61-64 recruited participants from diverse racial or ethnic groups and reported cultural adaptations to their interventions. Five (3.8%) of these trials54-56 included advice on regional or culturally adapted recipes and foods for specific ethnic groups. Two trials (1.5%)51-52 had interventions that were delivered by bilingual staff. One trial68 also reported that the intervention was designed for delivery in populations with limited literacy and numeracy and impaired access to health-promoting resources. While two trials56,69 recruited participants from workplace settings (an automobile manufacturer and a university; both were not considered to meet the PROGRESS-Plus occupation definition), and

Robertson C, et al. BMJ Open 2022;12:e054459. doi:10.1136/bmjopen-2021-054459

3
one trial recruited married participants, the trials did not report any attempts to alter their recruitment strategies or interventions to appeal to underserved occupation or social capital groups. The trials did not report recruitment strategies or adaptations to interventions for sexual orientation.

A further five trials (all from the USA) sought recruitment from specific racial or ethnic groups and reported intervention adaptations to increase cultural salience. Four of these trials included culturally specific dietary advice and recipes. One trial described including bilingual interventions and three trials described including interventionists from specific racial or ethnic groups. Two trials described using logos and programme identification ‘for African-Americans’, with one of these trials including a video greeting from an African-American principal investigator.

The number of trials reporting inclusion and exclusion criteria by protected characteristic groups is presented in Table 1. Four older trials (3.1%) did not report any inclusion criteria, and inclusion criteria were unclear in one further study. Seven (5.3%) trials did not report any explicit exclusion criteria and did not report that they had no exclusion criteria. Eight (6.1%) trials reported either full or partial justification for their exclusion criteria. Justification for exclusion criteria included prevention of poor adherence and losses to follow-up, such as substance abuse, mental health problems or cognitive impairment (that might, in the opinion of the investigators, hinder participation), lower BMI cut-offs for Asian people, non-English-language speakers where the intervention required English language comprehension, influence of pregnancy and breast feeding on weight, taking medications that influence weight, and contraindications or safety concerns associated with participating in the intervention (eg, risk of participants with cardiovascular disease participating in exercise programmes). Over half (58.0%) of the trials reported excluding people with mental health conditions and 44.2% excluded people with substance abuse or addiction issues. The majority of trials also excluded

| Protected characteristic | Inclusion | Unclear if the protected characteristic was targeted for inclusion or if the trial unintentionally recruited solely/mainly from the protected characteristic group, n (%) | Exclusion |
|--------------------------|-----------|---------------------------------------------------------------------------------------------------------------------------------|-----------|
| Place of residence/housing | 5 (3.8) | 0 | 0 |
| Race/ethnicity | 7 (5.3) | 5 (3.8) | 2 (1.5) |
| Occupation status | 0 | 0 | 0 |
| Women only | 19 (14.5) | 0 | 4 (3.1) |
| Pregnancy | 0 | 0 | 0 |
| Men only | 4 (3.0) | 0 | 1 (0.76) |
| Religion/belief | 1 (0.8) | 0 | 0 |
| Education/literacy | 0 | 0 | 0 |
| Socioeconomic status | 3 (2.3) | 3 (2.3) | 0 |
| Marital status | 1 (0.8) | 0 | 1 (0.8) |
| Older age | 2 (1.5) | 1 (0.8) | 0 |
| Physical health | 10 (7.6) | 0 | 0 |
| Diabetes type 1 | 0 | 0 | 0 |
| Diabetes type 2 | 28 (21.4) | 0 | 0 |
| Diabetes (type 1 and 2 or type not reported) | 0 | 0 | 0 |
| Mental health | 6 (4.6) | 0 | 0 |
| Substance abuse | 0 | 0 | 0 |
| Eating disorder | 0 | 0 | 0 |
| Language | 0 | 0 | 0 |

*Includes eight RCTs recruiting participants up to 75 years, one RCT recruited participants up to 76 years and three RCTs recruited participants aged up to 80 years.

RCTs, randomised controlled trials; REBALANCE, REview of Behaviour And Lifestyle interventions for severe obesity; AN evidenCE synthesis.
adults from older age groups and based on current or planned pregnancy.

Twenty-one (16.0%) trials were judged to have inclusion criteria that might have implicitly excluded certain disadvantaged groups, such as people who do not have healthcare insurance, people who do not belong to a particular religious community group, people without regular internet or telephone access, and English language comprehension. In a further 40 (30.5%) trials, it was unclear if trial recruitment could have implicitly excluded disadvantaged groups. Few trials reported their inclusion criteria so as to include particular underserved groups or were judged to have made efforts to maximise trial recruitment from these groups. When trial recruitment was targeted, this was usually to recruit women only (19 trials) or people with type 2 diabetes (28 trials).

**Reporting of baseline characteristics**

Details of the number of trials reporting baseline characteristics of their participants by each of the protected characteristic groups are presented in table 2. The majority of trials reported age (99.2%) and sex (97.7%) in their description of baseline participant characteristics. Just over half of the trials (58.0%) reported race or ethnicity. Education history was less well reported (40.5%). SES was reported by 22.9%, and occupation status by 21.4%. Of the trials that were not specifically for people with diabetes, six (4.6%) included diabetes in their reporting of baseline characteristics. Two (1.5%) trials reported whether people lived alone or not (coded as social capital). Few trials reported details of the other protected characteristics, and none reported details of gender reassignment, sexual orientation or pregnancy.

**Outcome reporting**

Details of the number of trials reporting outcomes by each of the protected characteristics are shown in table 3. Very few trials reported outcomes by protected characteristic groups. Where outcomes were reported by protected characteristics, the most common group was sex (47.3%), followed by race or ethnicity (16.8%).

**DISCUSSION**

**Main findings**

Our findings demonstrate that most trialists testing weight management strategies to help adults with severe obesity fail to consider populations who are most at risk of poorer health outcomes. Almost all trials were from high-income countries, where lower SES and income are associated with a greater prevalence of obesity, particularly severe obesity. Few trials reported adapting recruitment to appeal to underserved groups or reported culturally adapting their trial materials for ethnic groups or people with limited English language literacy or numeracy. This is concerning as limiting the accessibility or appeal of trials could limit the representativeness of the trial population, and thus limit the generalisability of trial findings. Only 6.1% of trials gave any justification for their exclusion.

**Table 2** The number (and per cent) of trials (n=131) reporting protected characteristics at baseline in the REBALANCE systematic review of RCTs

| Protected characteristic is reported at baseline for each intervention arm | Protected characteristic is reported at baseline for the whole trial | Total |
|---|---|---|
| Age | 126 (96.2%) | 4 (3.0%) | 130 (99.2%) |
| Physical health | 10 (7.6%) | 0 | 10 (7.6%) |
| Mental health | 10 (7.6%) | 0 | 10 (7.6%) |
| Diabetes | 6 (4.6%) | 0 | 6 (4.6%) |
| Sex | 126 (96.2%) | 2 (1.5%) | 128 (97.7%) |
| Gender reassignment | 0 | 0 | 0 |
| Sexual orientation | 0 | 0 | 0 |
| Marriage/civil partnership status | 38 (29.0%) | 0 | 38 (29.0%) |
| Pregnancy | 0 | 0 | 0 |
| Place of residence/housing | 6 (4.6%) | 0 | 6 (4.6%) |
| Occupation status | 27 (20.6%) | 0 | 28 (21.4%) |
| Education/literacy | 51 (38.9%) | 1 (0.8%) | 53 (40.5%) |
| Socioeconomic status | 29 (22.1%) | 2 (1.5%) | 30 (22.9%) |
| Social capital | 2 (1.5%) | 2 (1.5%) | 2 (1.5%) |
| Religion/belief | 1 (0.8%) | 0 | 1 (0.8%) |
| Race/ethnicity | 74 (56.5%) | 2 (1.5%) | 76 (58.0%) |
| PROGRESS-Plus | 2 (1.5%) | 0 | 2 (1.5%) |

PROGRESS, Place of residence, Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, Education, Socioeconomic status, Social capital; RCTs, randomised controlled trials; REBALANCE, Review of Behaviour And Lifestyle interventions for severe obesity: AN evidence synthesis.
criteria, yet more than half excluded participation for age or mental health reasons. Where justification for exclusion was reported, the rationale included excluding people who were deemed likely to have poor intervention adherence or were more likely to be lost to follow-up, such as people with substance abuse, cognitive impairment or mental health problems. Excluding these groups could lead to an unrealistic estimation of the real-world effectiveness of interventions. Just over half of the trials reported participants’ race or ethnicity, and only around one-fifth reported SES. Where outcomes were reported for underserved groups, the most common analysis was by sex (47.3%), followed by race or ethnicity (16.8%); however, where analyses were presented as subgroups, it was often unclear whether these analyses were planned or unplanned. Similarly, some smaller trials might have been underpowered to detect differences in treatment effects between subgroups, but this was also unclear from trial reporting. This finding was also demonstrated by Liu and colleagues,99 who highlighted a lack of transparent reporting of intentions to analyse race and ethnicity subgroups in Cochrane intervention reviews. Only 3.1% of the trials we reviewed reported outcomes according to SES. Few trials reported outcomes by the other protected characteristics.

Although we were limited by the available information in the published reports, our findings are concerning. In almost all trials, it is difficult to assess the generalisability of findings to the wider population of adults with severe obesity. There is clear evidence1–5 11 12 that underserved groups with lower incomes, less education, lower SES, intellectual and physical disabilities, or poorer mental health are more at risk of obesity, particularly severe obesity, in high-income countries, especially the USA which provided the majority of trials examined. We do not have relevant data to be able to comment on the reasons for poor reporting. Nevertheless, the lack of reporting for characteristics reflecting underserved groups suggests that trial investigators did not consider or faced barriers that prevented their inclusion in the design, recruitment, and analysis or reporting of their interventions.

Our finding that few trials adapted their recruitment methods or interventions to appeal to underserved groups suggests lack of engagement with underserved people with obesity in the design of services. This is important, given that a systematic review of qualitative research by Sutcliffe and colleagues100 showed how service users have perspectives that should inform weight management services to improve their reach. From systematic reviews, researchers have clearly demonstrated the need

### Table 3

| Characteristic | Trial recruitment was targeted at people from the protected characteristic group | One or more outcome(s) reported for the protected characteristic in planned subgroup analysis | One or more outcome(s) reported for the protected characteristic—unclear if subgroup analysis was preplanned | Total |
|----------------|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------|
| Older age      | 2 (1.5%)*                                                                       | 2 (1.5%)                                                                                     | 3 (2.3%)                                                                                         | 7 (5.3%) |
| Physical health| 10 (7.6%)                                                                        | 0                                                                                             | 0                                                                                               | 10 (7.6%) |
| Mental health  | 6 (4.6%)                                                                         | 0                                                                                             | 2 (1.5%)                                                                                         | 8 (6.1%) |
| Diabetes       | 28 (21.3%)                                                                        | 0                                                                                             | 1 (0.8%)                                                                                         | 29 (22.1%) |
| Sex            | 23 (17.5%)†                                                                      | 17 (13.0%)                                                                                   | 22 (16.8%)                                                                                      | 62 (47.3%) |
| Gender reassignment | 0                                                                                   | 0                                                                                             | 0                                                                                               | 0 |
| Sexual orientation | 0                                                                                   | 0                                                                                             | 0                                                                                               | 0 |
| Marriage/civil partnership status | 1 (0.8%)                                                                       | 1 (0.8%)                                                                                     | 3 (2.3%)                                                                                         | 5 (3.8%) |
| Pregnancy      | 0                                                                               | 0                                                                                             | 0                                                                                               | 0 |
| Place of residence/housing | 0                                                                               | 2 (1.5%)                                                                                     | 0                                                                                               | 2 (1.5%) |
| Occupation status | 2 (1.5%)                                                                       | 2 (1.5%)                                                                                     | 4 (3.1%)                                                                                         | 8 (6.1%) |
| Education/literacy | 0                                                                               | 1 (0.8%)                                                                                     | 6 (4.6%)                                                                                         | 7 (5.3%) |
| Socioeconomic status | 5 (3.8%)                                                                       | 4 (3.1%)                                                                                     | 3 (2.3%)                                                                                         | 12 (9.2%) |
| Social capital  | 1 (0.8%)                                                                         | 3 (2.3%)                                                                                     | 2 (1.5%)                                                                                         | 6 (4.6%) |
| Religion/belief | 1 (0.8%)                                                                         | 0                                                                                             | 1 (0.8%)                                                                                         | 1 (0.8%) |
| Race/ethnicity  | 8 (6.1%)                                                                         | 5 (3.8%)                                                                                     | 9 (6.9%)                                                                                         | 22 (16.8%) |
| PROGRESS-Plus  | 0                                                                               | 0                                                                                             | 0                                                                                               | 0 |

*Both trials recruited participants aged ≥65 years.
†Nineteen women-only trials, four men-only trials.
PROGRESS, Place of residence, Race/ethnicity/culture/language, Occupation, Gender/sex, Religion, Education, Socioeconomic status, Social capital, RCTs, randomised controlled trials; REBALANCE, REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis.
to involve communities in all stages of research in order to enhance the engagement and generalisability of that research, acknowledging that this requires extended time frames and greater costs. For example, Ni She and colleagues undertook a rapid realist review of the mechanisms and resources needed to engage underserved, seldom-heard groups in health and social care research, with items grouped by an expert panel under the headings of environmental and social planning, service provision, guidelines, fiscal measures, communication and marketing, and regulation and legislation. In the USA, Arnegard and colleagues have also called on the NIH’s stakeholder groups to redouble their efforts to encourage sex/gender-aware reporting of biomedical investigations. We endorse this call following the findings from our previous systematic review of weight management interventions for men with obesity. Our review highlighted the paucity of evidence for men, who are less likely to take part in weight management interventions, and the lack of engagement of men in all aspects of intervention design, and optimal trial recruitment processes of weight management.

While the reasons for the under-representation of underserved groups in RCTs are likely to be complex and multifaceted, with many known and unknown barriers to participation, there is evidence that, for some groups, willingness to participate is not a predominant factor. Mindful of the need to improve the engagement of underserved groups in research in the UK, the NIHR set up the INCLUDE Project, which has led to the INCLUDE ethnicity framework, providing four key questions on who should be involved in research, and how to facilitate involvement. Others have investigated and found a lack of external validity in trials for people with asthma, type 2 diabetes and neurological disease, or a failure to justify exclusion criteria in trials of cardiovascular disease prevention other than for safety reasons. These publications did not consider the SES or educational attainment of trial participants. In a systematic review of 305 trials of clinical conditions, He and colleagues found high exclusion rates in trials for people with hypertension (83.0%), lipid-lowering drugs in primary prevention (85.9%), type 2 diabetes (81.7%), chronic obstructive pulmonary disorder (COPD) (84.3%) and asthma (96.0%), with no strong evidence that exclusion rates had changed with time.

More recently, others have also highlighted the small number of intervention studies testing out weight management for underserved adults, or policies to assist socio-economically disadvantaged groups. A 2015 systematic review of interventions aimed at reducing socioeconomic inequalities for adults with obesity found that primary care-delivered tailored weight loss programmes and group weight loss interventions had the most evidence of potential effectiveness in reducing obesity, at least in the short term, among low-income women, but there were few individual-level intervention studies and a lack of long-term evidence of effectiveness.

Strengths and limitations
We used categories informed by the PROGRESS-Plus framework and the UK Equality Act 2010 as the key characteristics for identifying those underserved participants who should be considered for study design, public–patient involvement, recruitment, analysis and reporting, not just for trials of weight management, but trials generally. O’Neill and colleagues have shown how the prior PROGRESS framework can be used as an equity lens for systematic reviews and methodological studies; however, NIHR’s INCLUDE Project has recently published a more extensive list of categories of underserved groups to consider with regard to representation in trials.

Our literature search attempted to identify all long-term randomised trials published since 1990 for adults with BMI ≥35 kg/m² irrespective of the type of lifestyle intervention, including comparisons with orlistat and bariatric surgery. Although we included publications in any language from any country, we cannot exclude the possibility that we failed to find some trials, particularly those from low-income countries, which might not be listed in the databases we searched. While we originally contacted authors for all available additional materials relating to our main research question for the REBALANCE Project, we did not recontact authors to obtain additional information relating to the current analysis. We were also limited by poor reporting by trial authors. Some trials were statistically underpowered to detect subgroup differences, and this might explain under-reporting of underserved characteristics; however, this was unclear from the trial reports. It is also possible that some trialists were unable to obtain relevant baseline data for some underserved groups if this was deemed sensitive by an ethics committee, for example, sexual orientation. Nevertheless, we consider that most characteristics are pivotal to interpreting these trials into real-world guidance and services, so we would expect their presentation in trial publications, especially at baseline. We assessed long-term RCT evidence because it is most likely to inform guidance on weight management.

Recommendations for research
Trialists should improve reporting of their justification of inclusion and exclusion criteria to meet current Consolidated Standards of Reporting Trials (CONSORT) statement guidelines, and report sufficient data to allow comparisons between their populations and the populations for whom the interventions apply. Including core criteria for baseline reporting within the CONSORT checklist could help to improve the completeness of reporting of these factors. NIHR’s INCLUDE Project’s ethnicity framework provides important factors to consider with regard to ethnic groups (https://www.trial-forge.org/trial-forge-centre/include/), which can help provide transferable considerations for other underserved
CONCLUSIONS AND RECOMMENDATIONS FOR PRACTICE

Long-term RCTs of weight management in people with BMI $\geq 35$ kg/m$^2$ have inadequate representation of and engagement with underserved groups, who are particularly relevant for health and social care services. Thus, guidance for weight management research on how to improve the representation of underserved groups in clinical trials may improve the appropriateness of that research and help inform greater engagement of underserved communities with health and social care services.

Acknowledgements We thank the members of the REBALANCE Project and Advisory Groups for their contributions to the REBALANCE Project. We thank Shaun Treweek and Heidi Gardner, Health Services Research Unit, University of Aberdeen, for helpful discussions on trial generalisability and inclusion of underserved groups.

Contributors CR, MA-M, MC, MI and AA contributed to conception and design, acquisition of data, or analysis and interpretation of data, and revised data critically for important intellectual content of this manuscript. All authors critically reviewed the manuscript and approved the final version submitted for publication. CR takes responsibility for the integrity of the data and the accuracy of the data analysis. CR is the guarantor and accepts full responsibility for the finished work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

Funding The REBALANCE Study was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (project number: 15/09/04).

Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorates.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval Ethical approval was not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article, uploaded as supplemental information, or are available from the NHRR journals library (REBALANCE REVIEW) of Behaviour And Lifestyle interventions for severe obesity: AN evidence synthesis (nih.ac.uk)

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, and transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Clare Robertson http://orcid.org/0000-0001-6019-6795
Magaly Acves-Martins http://orcid.org/0000-0002-9441-142X
Moira Cruickshank http://orcid.org/0000-0002-5182-884X
Mari Imamura http://orcid.org/0000-0003-4871-0354
Alison Avenell http://orcid.org/0000-0003-4813-5628

REFERENCES

1 Booth HP, Charlton J, Guilford MC. Socioeconomic inequality in morbid obesity with body mass index more than 40 kg/m$^2$ in the United States and England. SSM Popul Health 2017;3:172–8.

2 Devaux M, Sassi F. Social inequalities in obesity and overweight in 11 OECD countries. Eur J Public Health 2013;23:464–9.

3 El-Sayed AM, Scarborough P, Galea S. Unevenly distributed: a systematic review of the health literature about socioeconomic inequalities in adult obesity in the United Kingdom. BMC Public Health 2012;12:18.

4 Hsieh K, Rimmer JH, Heller T. Obesity and associated factors in adults with intellectual disability. J Intell Disabil Res 2014;58:851–63.

5 Public Health England. Excess Weight and COVID-19: Insights from new evidence [Internet]. London: PHE publications, 2021. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/907966/PHE_insight_Excess_weight_and_COVID-19_FINAL.pdf

6 Phillips J. Tackling obesity: the role of the NHS in a whole-system approach. London: The Kings Fund, 2021.

7 Grech A, Allman-Farinelli M. Prevalence and period trends of overweight and obesity in Australian young adults. Eur J Clin Nutr 2016;70:1083–5.

8 Robertson C, Archibald D, Avenell A, et al. Systematic reviews of and integrated report on the quantitative, qualitative and economic evidence base for the management of obesity in men. Health Technol Assess 2014;18:vi–xi, xxiii–xci, 1–424.

9 Minet Kinge J, Morris S. Socioeconomic variation in the impact of obesity on health-related quality of life. Soc Sci Med 2010;71:1864–71.

10 Avenell A, Robertson C, Skea Z, et al. Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and economic evaluation. Health Technol Assess 2018;22:1-248.

11 Green MA, Rowe F. Explaining the widening distribution of body mass index: a decomposition analysis of trends for England, 2002–2004 and 2012–2014. Area2020;1–11.

12 Ogden CL, Fryar CD, Martin CB, et al. Trends in obesity prevalence by race and Hispanic origin—United States, 1999–2017. JAMA 2020;324:1208–10.

13 Menozzi K, Nathan A, Turrell G. Ethnic differences in overweight and obesity and the influence of acculturation on immigrant bodyweight: evidence from a national sample of Australian adults. BMC Public Health 2016;16:332.

14 New Zealand Ministry of Health. Obesity statistics, 2020. Available: https://www.health.govt.nz.nz-health-statistics/health-statistics-and-data-sets/obesity-statistics [Accessed Oct 2021].

15 U.S. Food and Drug Administration (FDA). Guidance for industry: collection of race and ethnicity data in clinical trials. Available: https://www.fda.gov/media/75453/download [Accessed Mar 2021].

16 U.S. Food and Drug Administration (FDA). Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies. Available: https://www.fda.gov/media/98866/download [Accessed Mar 2021].

17 U.S. Food and Drug Administration (FDA). Design considerations for devices intended for home use. Available: https://www.fda.gov/media/84830/download [Accessed Mar 2021].

18 National Institutes of Health [Internet]. U.S. 2019. Inclusion policies for research involving human subjects. Available: https://grants.nih.gov/policy/inclusion.htm [Accessed Mar 2021].

19 National Institute for Health Research [Internet]. London: The Institute; 2020 [cited February 2021]. Improving inclusion of under-served groups in clinical research: Guidance from the NIHR INCLUDE project. Available: www.nihr.ac.uk/documents/improving-
inclusion-of-under-served-groups-in-clinical-research-guidance-from-include-project/25435

Unger JM, Gralow JR, Albain KS, et al. Patient income level and cancer clinical trial participation: a prospective survey study. *JAMA Oncol* 2020;20:2109–17.

Smart A, Harrison E. The under-representation of socially disadvantaged groups in UK medical research. *EfEn Health* 2017;22:65–82.

Bakris G, Calhoun D, Egan B, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Clinically significant improved fitness and weight loss among overweight persons with serious mental illness. *Psychiatr Serv* 2013;64:729–36.

Brehm BJ, Lattin BL, Summer SS, et al. One-year comparison of a high-monounsaturated-fat diet with a high-carbohydrate diet in type 2 diabetes. *Diabetes Care* 2009;32:215–20.

Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK morbidity study. *Int J Clin Pract* 2004;58:494–500.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.

Bartels SJ, Pratt SI, Aschbrenner KA, et al. Olistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. *J Hypertens* 2004;22:599–606.
strategies for black and white adults with diabetes who live in medically underserved rural communities. *Am J Public Health* 2004;94:1736–42.

66 Perri MG, Limacher MC, Durning PE, et al. Extended-care programs for weight management in rural communities: the treatment of obesity in underserved rural settings (TOURS) randomized trial. *Arch Intern Med* 2008;168:2347–54.

67 Perri MG, Limacher MC, von Castel-Roberts K, et al. Comparative effectiveness of three doses of weight-loss counseling: two-year findings from the rural LITE trial. *Obesity* 2014;22:2293–300.

68 Bennett GG, Webster ET, Glasgow RE, et al. Obesity treatment for socioeconomically disadvantaged patients in primary care practice. *Arch Intern Med* 2012;172:565–74.

69 Østbye T, Stroo M, Brouwer RJN, et al. Steps to Health employee weight management randomized control trial: short-term follow-up results. *J Occup Health* 2015;57:95–6.

70 Wing RR, Marcus MD, Epstein LH, et al. A “family-based” approach to the treatment of obese type II diabetic patients. *J Consult Clin Psychol* 1991;59:156–62.

71 Poston WSC, Reeves RS, Haddock CK, et al. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. *Int J Obes Relat Metab Disord* 2003;27:1486–93.

72 Martin PD, Dutton GR, Rhode PC, et al. Weight loss maintenance following a primary care intervention for low-income minority women. *Obesity* 2008;16:2462–7.

73 Kumanjia SK, Shults J, Fassbender J, et al. Outpatient weight management in African-Americans: the Healthy Eating and Lifestyle Program (HELP) study. *Prev Med* 2005;41:488–502.

74 Kumanjia SK, Wadden TA, Shults J, et al. Trial of family and friend support for weight loss in African American adults. *Arch Intern Med* 1994;154:795–801.

75 Fitzgibbon ML, Stolley MR, Schiffer L, et al. Obesity Reduction Black Intervention Trial (ORBIT): 18-month results. *Obesity* 2010;18:2317–25.

76 Wadden TA, Berkowitz RL, Vogt RA, et al. Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. *Obes Res* 1997;5:218–26.

77 Wadden TA, Vogt RA, Foster GD, et al. Exercise and the maintenance of weight loss: 1-year follow-up of a controlled clinical trial. *J Consult Clin Psychol* 1998;66:429–33.

78 Torgerson JS, Lissner L, Lindroos AK, et al. VLCD plus dietary and behavioural support versus support alone in the treatment of severe obesity. A randomised two-year clinical trial. *Int J Obes Relat Metab Disord* 1997;21:987–94.

79 Melin I, Karlström B, Lappalainen R, et al. A programme of behaviour modification and nutrition counselling in the treatment of obesity: a randomised 2-year clinical trial. *Int J Obes Relat Metab Disord* 2003;27:1127–35.

80 Pascale RW, Wing RR, Butler BA, et al. Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes. *Diabetes Care* 1995;18:1241–8.

81 Perri MG, Nezu AM, Mckelvey WF, et al. Relapse prevention training and problem-solving therapy in the long-term management of obesity. *J Consult Clin Psychol* 2001;69:722–6.

82 Richelsen B, Tonstad S, Røssner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. *Diabetes Care* 2007;30:272–32.

83 Cummings DE, Arterburn DE, Westbrook EO, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomized controlled trial. *Diabetologia* 2016;59:945–53.

84 Daubenmier J, Moran PJ, Kristeller J, et al. Effects of a mindfulness-based weight loss intervention in adults with obesity: a randomized clinical trial. *Obesity* 2016;24:794–804.

85 Dixon JB, Schachter LM, O’Brien PE, et al. Surgical vs conventional therapy for weight-loss treatment of obstructive sleep apnea: a randomized controlled trial. *JAMA* 2012;308:1142–9.

86 Dutton GR, Nackers LM, Dubayk PJ, et al. A randomized trial comparing weight loss treatment delivered in large versus small groups. *Int J Behav Nutr Phys Act* 2014;11:123.

87 Latner JD, Ghadirian BC, Winkenbauer JM, et al. Community-Based behavioral weight-loss treatment: long-term maintenance of weight loss, physiological, and psychological outcomes. *Behav Res Ther* 2013;51:451–9.

88 Lowe MR, Butryn ML, Thomas JG, et al. Meal replacements, reduced energy density eating, and weight loss maintenance in primary care patients: a randomized controlled trial. *Obesity* 2014;22:94–100.

89 Christensen P, Frederiksen R, Bliddal H, et al. Comparison of three weight maintenance programs on cardiovascular risk, bone and vitamins in sedentary older adults. *Obesity* 2013;21:1982–90.

90 Damschroder LJ, Lutes LD, Kirsch S, et al. Small-changes obesity treatment among veterans: 12-month outcomes. *Am J Prev Med* 2014;47:541–53.

91 Eaton CB, Hartman SJ, Perzanowski E, et al. A randomized clinical trial of a tailored lifestyle intervention for obese, sedentary primary care patients. *Ann Fam Med* 2016;14:311–9.

92 Wolf AM, Conwayay MR, Crowther JQ, et al. Translating lifestyle intervention to practice in obese patients with type 2 diabetes: improving control with activity and nutrition (ICAN) study. *Diabetes Care* 2004;27:1570–6.

93 Mensinga JL, Caalogaer RM, Stranges S, et al. A weight-neutral versus weight loss approach for health promotion in women with high BMI: a randomized-controlled trial. *Appetite* 2016;105:384–7.

94 Nackers LM, Middleton KR, Dubayk PJ, et al. Effects of prescribing 1,000 versus 1,500 kilocalories per day in the behavioral treatment of obesity: a randomized trial. *Obesity* 2013;21:2487–94.

95 Nilson V, Bakke PS, Gallesøe F. Effects of lifestyle intervention in persons at risk for type 2 diabetes mellitus - results from a randomised, controlled trial. *BMJ Public Health* 2011;11:893.

96 O’Neill PM, Miller-Kovach K, Tuerk PW, et al. Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. *Obesity* 2016;24:2269–77.

97 Djuric Z, Mirasolo J, Kimbreugh L, et al. A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors. *J Natl Med Assoc* 2009;101:552–64.

98 Richardson A, Saunders RR, Lake M, et al. Comparison of two weight management programs for adults with mobility impairments. *Disabil Health J* 2015;8:61–9.

99 Liu P, Ross JS, Ioannidis JP, et al. Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews. *Clin Trials* 2010;7:231–4.

100 Sutcliffe K, Melendez-Torres GJ, Burchett HED, et al. The importance of service-users’ perspectives: a systematic review of qualitative evidence reveals overlooked critical features of weight management programmes. *Health Expect* 2018;21:563–73.

101 De las Nueces D, Hwang J, DiGiulio A. A systematic review of community-based participatory research to enhance clinical trials in racial and ethnic minority groups. *Health Serv Res* 2012;47:1383–86.

102 Ni She É, Morton S, Lambert V, et al. Clarifying the mechanisms and resources that enable the reciprocal involvement of seldom heard groups in health and social care research: a collaborative rapid realist review process. *Health Expect* 2019;22:298–306.

103 Arnegard ME, Whiten LA, Hunter C, et al. Sex as a biological variable: a 5-year progress report and call to action. *J Womens Health* 2020;29:858–64.

104 Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? *PLoS Med* 2006;3:e19.

105 Trial Forge [Internet]. Aberdeen, Scotland: Trial Forge; 2020 [cited February 2019]. The INCLUDE ethnicity framework. Available: https://www.trialforge.org/trial-forge-centre/include/

106 Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? *Thorax* 2007;62:219–23.

107 Saunders C, Byrne CD, Guthrie B, et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? *Diabet Med* 2013;30:300–8.

108 Hoppe C, Kerr D. Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes. *Lancet Diabetes Endocrinol* 2017;5:13.

109 Trivedi RB, Humphreys K. Participant exclusion criteria in treatment research on neurological disorders: are unrepresentative study samples problematic? *J Clin Trials* 2015;4:20–5.

110 Schmidt AF, Groenewold RHV, van Delden JJM, et al. Justification of exclusion criteria was underestimated in a report of cardiovascular trials. *J Clin Epidemiol* 2014;67:635–44.

111 He J, Morales DR, Guthrie B. Ethnicity rates in randomized controlled trials of treatments for physical conditions: a systematic review. *Trials* 2020;21:228.

112 Hayba N, Partridge SR, Nour MM, et al. Effectiveness of lifestyle interventions for preventing harmful weight gain among young adults from lower socioeconomic status and ethnically diverse backgrounds: a systematic review. *Obes Rev* 2018;19:333–66.

113 Olstad DL, Anclito R, Teychenne M, et al. Can targeted policies reduce obesity and improve obesity-related behaviours in...
socioeconomically disadvantaged populations? A systematic review. Obes Rev 2017;18:791–807.

114 Bambra CL, Hillier FC, Cairns J-M, et al. How effective are interventions at reducing socioeconomic inequalities in obesity among children and adults? two systematic reviews. Public Health Res 2015;3:1–446.

115 Witham MD, Anderson E, Carroll C, et al. Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process. Trials 2020;21:694.

116 Moher D, Hopewell S, Schulz KF, et al. Consort 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.